Advertisement

Lymphedema pp 477-488 | Cite as

Clinical Overview-Diagnosis and Management

  • Gurusamy Manokaran
Chapter

Abstract

There are about 120 million people at risk for and 70 million people have established lymphatic filariasis, of which 40 million are suffering from lymphedema; thus, it is very important for medical, paramedic and health planners to understand this disease and to provide morbidity control including surgery for these unfortunate patients. The World Health Organization is working toward elimination of lymphatic filariasis by 2020.1-17

Keywords

Adult Worm Lymphatic Filariasis Diethyl Carbamazine Lymph Node Transfer Pressure Garment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Molyneux DH, Zagaria N. Lymphatic filariasis elimination: progress in global programme development. Ann Trop Med Parasitol. 2002;96:S15-S40.PubMedCrossRefGoogle Scholar
  2. 2.
    Ottesen EA, Duke BOL, Karam M, Behbehani K. Strategies and tools for the elimination of lymphatic filariasis. Bull World Health Organ. 1997;75:491-503.PubMedGoogle Scholar
  3. 3.
    Ottesen EA. Lymphatic filariasis: treatment, control and elimination. Adv Parasitol. 2006;61:395-441.PubMedCrossRefGoogle Scholar
  4. 4.
    World Health Organization. Global programme to eliminate lymphatic filariasis: progress report for 2004. Wkly Epidemiol Rec. 2005;80:202-212.Google Scholar
  5. 5.
    World Health Organization. Global programme to eliminate lymphatic filariasis: progress report on mass drug administrations in 2005. Wkly Epidemiol Rec. 2006;22:221-232.Google Scholar
  6. 6.
    World Health Organization. Global programme to eliminate lymphatic filariasis: progress report on mass drug administration in 2006. Wkly Epidemiol Rec. 2007;82:361-380.Google Scholar
  7. 7.
    World Health Organization. Global programme to eliminate lymphatic filariasis: progress report on mass drug administration in 2007. Wkly Epidemiol Rec. 2008;83:333-348.Google Scholar
  8. 8.
    World Health Organization (2002) Annual Report on Lymphatic Filariasis 2001. Geneva. http://whqlibdoc.who.int/hq/2002/WHO_CDS_CPE_CEE_2002.28.pdf.
  9. 9.
    World Health Organization (2003) Annual Report on Lymphatic Filariasis 2002. Geneva. http://whqlibdoc.who.int/hq/2003/WHO_CDS_CPE_CEE_2003.38.pdf.
  10. 10.
    World Health Organization (2004) Annual Report on Lymphatic Filariasis 2003. Geneva. http://whqlibdoc.who.int/hq/2005/WHO_CDS_CPE_CEE_2005.52.pdf.
  11. 11.
    Dreyer G, Ottesen EA, Galdino E, Andrade L, Rocha A, et al. Renal abnormalities in microfilaremic patients with Bancroftian filariasis. Am J Trop Med Hyg. 1992;46:745-751.PubMedGoogle Scholar
  12. 12.
    Dreyer G, Figueredo-Silva J, Carvalho K, Amaral F, Ottesen EA. Lymphatic filariasis in ­children: adenopathy and its evolution in two young girls. Am J Trop Med Hyg. 2001;65:204-207.PubMedGoogle Scholar
  13. 13.
    Schlemper BR, Steindel M, Grisard EC, Carvalho-Pinto CJ, Bernardini OJ, et al. Elimination of bancroftian filariasis (Wuchereria bancrofti) in Santa Catarina state, Brazil. Trop Med Int Health. 2000;5:848-854.PubMedCrossRefGoogle Scholar
  14. 14.
    Bockarie MJ, Ibam E, Alexander NDE, Hyun P, Dimber Z, et al. Towards eliminating lymphatic filariasis in Papua New Guinea: impact of annual single-dose mass treatment on transmission of Wuchereria bancrofti in East Sepik Province. PNG Med J. 2000;43:172-182.Google Scholar
  15. 15.
    Grady CA, de Rochars MB, Direny AN, Orelus JN, Wendt J, et al. Endpoints for lymphatic filariasis programs. Emerg Infect Dis J. 2007;13:608-610.CrossRefGoogle Scholar
  16. 16.
    Chhotray GP, Ranjit MR, Mohapatra M. Occurrence of asymptomatic microscopic haematuria in a filarial endemic area of Orissa, India. J Commun Dis. 2000;32:85-93.PubMedGoogle Scholar
  17. 17.
    Dreyer G, Addiss D, Dreyer P, Noroes J. Basic Lymphedema Management: Treatment and Prevention of Problems Associated with Lymphatic Filariasis. Hollis: Hollis Publishing Company; 2002.Google Scholar
  18. 18.
    Ottesen EA. Infection and disease in lymphatic filariasis: an immunological perspective. Parasitology. 1992;104:S71-S79.PubMedCrossRefGoogle Scholar
  19. 19.
    Dreyer G, Ottesen EA, Galdino E, et al. Renal abnormalities in microfilaremic patients with bancroftian filariasis. Am J Trop Med Hyg. 1992;46:745-751.PubMedGoogle Scholar
  20. 20.
    Freedman DO, de Almeida Filho PJ, Besh S, et al. Lymphoscintigraphic analysis of lymphatic abnormalities in symptomatic and asymptomatic human filariasis. J Infect Dis. 1994;170:927-933.PubMedCrossRefGoogle Scholar
  21. 21.
    Noroes J, Addis D, Amaral F, et al. Occurrence of living adult Wuchereria bancrofti in the scrotal area of men with microfilaremia. Trans R Soc Trop Med Hyg. 1996;90:55-56.PubMedCrossRefGoogle Scholar
  22. 22.
    Pani SP, Yuvaraj J, Vanamail D, et al. Episodic adenolymphangitis and lymphoedema in patients with bancroftian filariasis. Trans R Soc Trop Med Hyg. 1992;89:72-74.CrossRefGoogle Scholar
  23. 23.
    Ottesen EA, Nutman TB. Tropical pulmonary eosinophilia. Annu Rev Med. 1992;43:417-424.PubMedCrossRefGoogle Scholar
  24. 24.
    Molyneux DH, Bradley M, Hoerauf A, Kyelem D, Taylor MJ. Mass drug treatment for lymphatic filariasis and onchocerciasis. Trends Parasitol. 2003;19(11):516-522.PubMedCrossRefGoogle Scholar
  25. 25.
    Bosshardt SC et al. Prophylactic activity of tetracycline against Brugia pahangi infection in jirds (Meriones unguiculatus). J Parasitol. 1993;79:775-777.PubMedCrossRefGoogle Scholar
  26. 26.
    McCall JW et al. Wolbachia and the antifilarial properties of tetracycline. An untold story. Ital J Zool. 1999;66:7-10.CrossRefGoogle Scholar
  27. 27.
    Bandi C et al. Effects of tetracycline on the filarial worms Brugia pahangi and Dirofilaria immitis and their bacterial endosymbionts Wolbachia. Int J Parasitol. 1999;29:357-364.PubMedCrossRefGoogle Scholar
  28. 28.
    Hoerauf A. et al. Targeting of Wolbachia in Litomosoides sigmodontis: comparison of tetracycline with chloramphenicol, macrolides and ciprofloxacin. Trop Med Int Hlth (in press)Google Scholar
  29. 29.
    Townson S et al. The activity of rifampicin, oxytetracycline and chloramphenicol against Onchocerca lienalis and O. gutturosa. Trans R Soc Trop Med Hyg. 1999;93:123-124.Google Scholar
  30. 30.
    Schuetz A, Addiss DG, Eberhard ML, Lammie PJ. Evaluation of the whole blood filariasis ICT test for short-term monitoring after antifilarial treatment. Am J Trop Med Hyg. 2000;62(4):502-503.PubMedGoogle Scholar
  31. 31.
    Weil GJ, Lammie PJ, Weiss N. The ICT Filariasis Test: a rapid-format antigen test for diagnosis of bancroftian filariasis. Parasitol Today. 1997;13(10):401-404.PubMedCrossRefGoogle Scholar
  32. 32.
    Amaral F, Dreyer G, Figueredo-Silva J, et al. Live adult worms detected by ultrasonography in human Bancroftian filariasis. Am J Trop Med Hyg. 1994;50:753-757.PubMedGoogle Scholar
  33. 33.
    Dreyer G, Santos A, Noroes J, Amaral F, Addiss D. Ultrasonographic detection of living adult Wuchereria bancrofti using a 3.5-MHz transducer. Am J Trop Med Hyg. 1998;59:399-403.PubMedGoogle Scholar
  34. 34.
    Homeida MA, Mackenzie CD, Williams JF, Ghalib HW. The detection of onchocercal nodules by ultrasound technique. Trans R Soc Trop Med Hyg. 1986;80:570-571.PubMedCrossRefGoogle Scholar
  35. 35.
    Leichsenring M, Troger J, Nelle M, Buttner DW, Darge K, Doehring-Schwerdtfeger E. Ultrasonographical investigations of onchocerciasis in Liberia. Am J Trop Med Hyg. 1990;43:380-385.PubMedGoogle Scholar
  36. 36.
    Shelley S, Manokaran G, Indirani M, Gokhale S, Anirudhan N. Lymphoscintigraphy as a diagnostic tool in patients with lymphedema of filarial origin—an Indian study. Lymphology. 2006;39(2):69-75.PubMedGoogle Scholar
  37. 37.
    Szuba A, Shin WS, Strauss HW, Rockson S. The third circulation: radionuclide lymphoscintigraphy in the evaluation of lymphedema. J Nucl Med. 2003;44:43-57.PubMedGoogle Scholar
  38. 38.
    Sherman A, Ter-Pogossian M. Lymph node concentration of radioactive colloidal gold following interstitial injection. Cancer. 1953;6:1238-1240.PubMedCrossRefGoogle Scholar
  39. 39.
    Nawaz K, Hamad MM, Sedek S, Awdeh M, Eklof B, Abdel-Dayem HM. Dynamic lymph flow imaging in lymphedema: normal and abnormal patterns. Clin Nucl Med. 1986;11:653-658.PubMedCrossRefGoogle Scholar
  40. 40.
    Werner GT, Scheck R, Kaiserling E. Magnetic resonance imaging of peripheral lymphedema. Lymphology. 1998;31:34-36.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2011

Authors and Affiliations

  • Gurusamy Manokaran
    • 1
  1. 1.Department of Plastic and Reconstructive Surgery and LymphologistApollo HospitalsChennaiIndia

Personalised recommendations